Results 111 to 120 of about 769 (187)

Apalutamide-induced severe hypothyroidism: case series and practice recommendations for thyroid management. [PDF]

Eur Thyroid J
David K, Van Crombrugge P, Van der Biest AM, D'Hondt F, Claessens F, Giesen A, Joniau S, Decallonne B.   +7 more
europepmc   +1 more source

LC-MS/MS Method for Therapeutic Drug Monitoring of Abiraterone, Darolutamide, Apalutamide, Enzalutamide, and Metabolites in Prostate Cancer Patients. [PDF]

Int J Mol Sci
Posocco B, Pasin D, De Cesaro N, Pivetta A, Gagno S, Canil G, Cecchin E, Cecchin R, Speziani S, Dri A, Bortolus G, Spina M, Santarossa S, Puglisi F, Fratino L, Cecchin E.   +15 more
europepmc   +1 more source

Matching-adjusted indirect comparison of enzalutamide versus apalutamide with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer. [PDF]

Future Oncol
Azad AA, Pandya BJ, Bhadauria HS, Berrak E, Daki V, Martins P, Kim J, Serikoff A, Baio G, Armstrong AJ.   +9 more
europepmc   +1 more source

Cost-effectiveness analysis of second-generation androgen receptor antagonists for the treatment of metastatic hormone-sensitive prostate cancer. [PDF]

Front Public Health
Yang Y, Chen YQ, Huang LZ, Chen Y.
europepmc   +1 more source

PSMA expression assessed by [¹⁸F]PSMA-1007 PET/CT imaging in metastatic hormone-sensitive prostate cancer patients treated with apalutamide. [PDF]

Cancer Imaging
Berg EK, Kunte SC, Zahner J, Holzgreve A, Aydogdu CD, Schmid HP, Eismann L, Rodler S, Unterrainer M, Werner RA, Stief CG, Unterrainer LM, Casuscelli J.   +12 more
europepmc   +1 more source

Severe cutaneous adverse reactions associated with second-generation androgen receptor antagonists in prostate cancer patients. [PDF]

PLoS One
Liu J, Liu X, Zeng H, Tong Y, Chen Z, Dong Z.   +5 more
europepmc   +1 more source

Genetic Predictors of Progression and Skin Rash in Japanese mCSPC Patients Treated With Apalutamide: CUARTET Study. [PDF]

Cancer Sci
Shiota M, Naiki T, Hatano K, Yokomizo A, Tsuchiya H, Takahashi Y, Nakayama T, Yoshida M, Uemura H.   +8 more
europepmc   +1 more source

Cutaneous Adverse Reactions to Apalutamide: Case Series with Clinical and Pathological Correlations. [PDF]

Acta Derm Venereol
Gil-Lianes J, Amat-Samaranch V, Giavedoni P, Vilaseca A, Córdoba Sánchez J, Alamon-Reig F, Castillo P, Garcia AP, Pascal M, Carrera C.   +9 more
europepmc   +1 more source

Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer. [PDF]

Cancer Med
Miura H, Yamamoto H, Okuyama Y, Ishi N, Tanaka R, Oishi T, Yoneyama F, Hamaya T, Togashi K, Fujita N, Okamoto T, Ohyama C, Hatakeyama S.   +12 more
europepmc   +1 more source

Comparison of deep prostate-specific antigen response in Black patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide. [PDF]

J Comp Eff Res
Lowentritt BH, Burbage S, Khilfeh I, Pilon D, Du S, Rossi C, Kinkead F, Diaz L, Brown G.   +8 more
europepmc   +1 more source